U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. Performance Data
  4. FDA-TRACK: Agency-wide Program Performance
  5. FDA-TRACK: Center for Biologics Evaluation and Research - Goal 4
  1. FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: Center for Biologics Evaluation and Research - Goal 4

FDA-TRACK: Biologics
FDA-TRACK Home Page

FDA's Center for Biologics Evaluation and Research (CBER) regulates biological products for human use under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. CBER protects and advances the public health by ensuring that biological products are safe and effective and available to those who need them. CBER also provides the public with information to promote the safe and appropriate use of biological products.

CBER leadership understands the Center cannot accomplish mission-critical initiatives without an aligned strategy and organizational accountability. To manage for strategic excellence and organizational accountability, CBER relies on the Offices that provide internal program support. These Offices work collaboratively to advance and maintain a skilled and experienced workforce adaptable to an everchanging environment.

Goal 4: Manage for Strategic Excellence and Organizational Accountability

 

 

Download Goal 4 Dataset

Note:  The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons.

Sign up to receive FDA-TRACK updates

Get regular FDA email updates delivered on this topic to your inbox.

Back to Top